Mandate roundup: IPE-Quest, NPRF, Lightstone

first_imgSeparately, European institutional investor is also looking for a manager to oversee a $80m investment grade corporate bond mandate. Managers applying for search QN1413 should apply the Bank of America Merrill Lynch US Corporate Index (C0A0) as a benchmark.All other criteria, including minimum AUM for similar mandates and managers, reflect search QN 1412. Applications for both searches are welcome until 6 June, stating gross of fees performance to the end of March.Meanwhile, Ireland’s National Pensions Reserve Fund (NPRF) has committed €10m to a life sciences fund managed by Lightstone Ventures.The reserve fund’s sixth investment in support of the Innovation Fund Ireland – a government initiative to support Irish start-ups with venture capital funding, will be to Lightstone Ventures I – a fund targeting early stage investments in medical device and pharmaceutical companies.NPRF chairman Paul Carty said: “The life science industry offers great potential for Ireland and Lightstone will provide emerging businesses in this exciting sector with a valuable new source of funding and expertise.”The Lightstone vehicle, targeting a raise of $170m, made its first investment in January this year.The IPE.com news team is unable to answer any further questions about IPE-Quest tender notices to protect the interests of clients conducting the search. To obtain information directly from IPE-Quest, please contact Jayna Vishram on +44 (0) 20 7261 4630 or email jayna.vishram@ipe-quest.com. A European institutional investor is seeking an asset manager for a $80m (€58m) high yield corporate debt mandate, using IPE-Quest.According to search QN1412, the US corporate bond mandate should focus on core companies, only investing in firms that issue debt in US dollars, are listed in the US by non European Union based firms.The investment should be actively managed, with performance measured against the Bank of America Merrill Lynch US High Yield Master II Index (H0A0).Interested managers should manage at least $500m in similar mandates with a minimum track record of three years, but preferably five. The manager should furthermore have total assets under management (AUM) of $5bn.last_img read more

Homes, Drivers Impacted By Batesville Power Outage

first_imgAn afternoon electric outage is impacting hundreds of households and businesses as well as traffic in Batesville.There are approximately 938 customers in Batesville and Oldenburg without power. It was first reported at 3:59 p.m. and Duke Energy estimates the power to be restored around 6 p.m.Five traffic signals between S.R. 229/S.R. 46 and Kroger are also not working properly. Emergency crews are helping direct traffic this afternoon.Stay tuned to your hometown station for the latest on this developing story.last_img

FDA Strengthens Warnings On Uterine Surgical Tool

first_imgFDA Strengthens Warnings On Uterine Surgical Tool The device, called a morcellator, should no longer be used in the “vast majority” of women, the FDA says, because it can spread cancerous tissue. The Washington Post: FDA Toughens Warning That Uterine Procedure Can Spread Cancer USA Today: FDA Warns Gynecologic Device Has Spread Cancer The New York Times: F.D.A. Issues Caution On Use Of Uterine Surgery Device That Can Spread Cancer The top U.S. health regulator warned Monday that a common surgical tool shouldn’t be used on most women during hysterectomies, a decision that caps nearly a year of debate and is expected to sharply curtail a procedure that the agency said can spread hidden cancer. The Food and Drug Administration used its authority to call for an immediate “black box” warning for laparoscopic power morcellators, the strongest caution the agency issues. Typically, such warnings on product labels undergo a lengthy comment period before being completed, lawyers for device makers said. (Kamp and Levitz, 11/24) The US Food and Drug Administration Monday warned against a gynecologic device that has spread cancer in women who thought they had harmless fibroids. In the last year, two-dozen women have reported that their cancer was made worse by the device, called a power morcellator, which turned a treatable condition into a life-threatening disease. (Weintraub, 11/24) This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.center_img The Wall Street Journal: Surgical Tool Gets Strongest Warning The Food and Drug Administration strengthened its warnings Monday against the use of a controversial uterine surgical technique, recommending that doctors avoid using laparoscopic power morcellators to remove uterine growths in the vast majority of women because of the risk of spreading hidden cancers. … The warnings, which come seven months after the FDA first recommended against the widespread use of the procedure, would inform patients that using power morcellators to remove uterine growths could unwittingly spread cancer inside their bodies and decrease the odds of long-term survival. (Dennis, 11/24) A power device used during uterine surgery in at least 50,000 women a year in the United States risks spreading cancerous tissue and should no longer be used in “the vast majority” of women, the Food and Drug Administration said on Monday. The tools, laparoscopic power morcellators, have been widely used in operations to remove fibroid tumors from the uterus, or to remove the entire uterus. Morcellators cut tissue into pieces that can be pulled out through the tiny incisions made during minimally invasive surgery. (Grady, 11/24) The FDA has warned against using laparoscopic power morcellators for the majority of women having growths removed from their uterus. The decision comes after a growing awareness that the devices can spread and worsen hidden cancers. (Burton, 11/24) The Wall Street Journal: 5 Questions About The FDA Warning On Morcellators, Uterine Fibroids last_img read more